Minaris Advanced Therapies

What Minaris Advanced Therapies does

Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies. The company serves biotech and pharmaceutical clients developing advanced therapy medicinal products (ATMPs), offering end-to-end services from process development and analytical development through cGMP manufacturing and biosafety testing. Its target customer base ranges from emerging clinical-stage biotechs to large pharmaceutical companies commercializing gene therapies, cell therapies, and viral vector-based treatments.

The company's core technology platforms include TESSA®, a plasmid-free AAV production system claiming up to 30x higher yields and up to 80% full capsids at scales up to 2,000L; XOFLX®, stable lentiviral packaging and producer cell lines that reduce plasmid transfection requirements; SnapFast™ modular plasmids for viral vector generation; and AgentSCREEN™, a GMP-qualified NGS platform for adventitious virus detection. Manufacturing operates across five sites in the United States (Allendale, Philadelphia), Europe (Germany), and Asia-Pacific (Japan, Singapore), supported by 60+ GMP clean rooms and 600,000 sq ft of infrastructure, with a documented track record of 7,500+ GMP batches and 25+ commercial products. The testing division operates from a 140,000 ft² dedicated facility offering biosafety, viral clearance, potency, stability, and lot release testing.

Minaris generates revenue through project-based CDMO contracts for clinical and commercial GMP manufacturing, supplemented by technology licensing royalties (notably TESSA® to Janssen). Pricing is custom and quote-based, with multi-year manufacturing agreements typical. The company is privately held by Altaris Capital Partners, which in 2025 unified Advanced Therapies, LLC and Minaris Regenerative Medicine under the unified Minaris Advanced Therapies brand, creating an integrated CDMO where analytics and QC are embedded at every stage of the lifecycle. Regulatory certifications span FDA, EMA, PMDA, MFDS, TGA, and USDA, enabling global commercial supply.

Name

Minaris Advanced Therapies

Legal name

Minaris Advanced Therapies, LLC

Website

https://minaris.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Minaris Advanced Therapies is a global cell and gene therapy CDMO offering process development, cGMP manufacturing of viral vectors and cell therapies, and biosafety/analytical testing services to biotech and pharmaceutical clients across the US, Europe, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy CDMO

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

akta.pro secondary industries

Cell Therapy CDMO (HLAGABAD), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

Keywords

• Cell therapy CDMO
• Gene therapy manufacturing
• Viral vector production
• AAV lentiviral manufacturing
• Biologics testing services

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. GMP CDMO Manufacturing Services: Minaris generates revenue by providing contract development and manufacturing services for cell and gene therapy products. Services include GMP manufacturing of viral vectors, cell therapies, and plasmid DNA. Revenue is derived from project-based contracts with biotech and pharmaceutical clients, typically multi-year manufacturing agreements for clinical and commercial supply.
2. Technology Licensing (TESSA®): Revenue from licensing proprietary AAV production technology (TESSA®) to pharmaceutical partners such as Janssen for use in their advanced therapy programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) that provides process development, GMP manufacturing, and commercial supply services for cell therapies and viral vector-based gene therapies, supported by an integrated GMP-compliant analytical and biosafety testing laboratory. Its offerings span plasmid engineering, cell banking, cell line development, technology transfer, viral vector and cell therapy process development, GMP manufacturing up to 2,000L scale, and a comprehensive testing services portfolio including biosafety, potency, stability, lot release, and viral clearance testing. The company serves biotech and pharmaceutical companies developing advanced therapy medicinal products across the US, Europe, and Asia-Pacific.

Product overview

Minaris Advanced Therapies is a global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) offering an integrated platform combining manufacturing and testing services. The core portfolio includes Cell Therapy CDMO and Gene Therapy CDMO services supported by proprietary technology platforms (TESSA® for AAV production, XOFLX® for lentiviral vectors, and SnapFast™ plasmids) for process development, GMP manufacturing, and commercial supply. Minaris Advanced Testing provides comprehensive biosafety and analytical testing services including Analytical Development, Assay Transfer, Biosafety Testing, Cell Line Characterization, Lot Release, Potency Testing, Stability Testing, and Viral Clearance, all delivered through a 140,000 ft² dedicated testing facility. The company also offers Technology Transfer and Regulatory Support services. Products operate under globally harmonized quality systems with manufacturing facilities in US, Germany, and Japan, and testing facilities in Philadelphia.

Differentiator

Problem solved

Functional benefit

Brands

• AgentSCREEN™: GMP-qualified Next Generation Sequencing (NGS) platform for adventitious virus detection with a 28-day turnaround time.

Products and services

• SnapFast™ Plasmids Modular, off-the-shelf plasmid products for viral vector generation including LVV, AAV, and adenovirus systems, enabling rapid implementation without custom vector design delays; targeted at cell and gene therapy developers and CDMO clients.
• Cell Banking Research, master and working cell bank generation under cGMP conditions with integrated characterization and release testing for global regulatory submissions; targeted at cell and gene therapy developers.
• TESSA® AAV Production Technology Proprietary plasmid-free AAV production system using helper-virus-free technology delivering up to 30x higher yields and up to 80% full capsids, scalable to 2,000L and beyond; targeted at gene therapy developers and partners (e.g., Janssen).
• XOFLX® Lentiviral Packaging & Producer Cell Lines Stable lentiviral packaging and producer cell line platforms that reduce or eliminate plasmid transfection requirements, enabling scalable, cost-effective LVV production with reduced batch-to-batch variability; targeted at CAR-T and cell therapy developers.
• Cell Line Development Engineering and development of research, production, and platform cell lines including packaging lines, producer lines, and engineered effector cells with full regulatory compliance and traceability; targeted at cell and gene therapy developers.
• Technology Transfer Structured technology transfer services supporting horizontal (site-to-site) and vertical (development-to-manufacturing) transfers with comprehensive gap assessments, bridging studies, and regulatory documentation; targeted at cell and gene therapy developers transitioning processes.
• Cell Therapy Process & Analytical Development Process development for scalable cell therapy manufacturing with expertise in CAR-T, TCR-T, TIL, NK, HSC, MSC, and iPSC platforms, including gene editing and closed automated workflows; targeted at cell therapy developers.
• Cell Therapy GMP Manufacturing Clinical and commercial-scale GMP manufacturing for autologous and allogeneic cell therapies from facilities in the US, Germany, and Japan with globally harmonized quality systems; targeted at cell therapy developers from clinical through commercial supply.
• Viral Vector Services End-to-end viral vector solutions spanning AAV, lentivirus, retrovirus, and adenovirus platforms from early-stage molecular discovery through cGMP manufacturing at up to 2,000L scale; targeted at gene therapy developers.
• Viral Vector Process Development Process development for AAV and LVV platforms including upstream optimization, scalable single-use bioreactor systems up to 200L, and downstream purification strategies; targeted at gene therapy developers.
• Viral Vector GMP Manufacturing GMP manufacturing for viral vectors including AAV and LVV using suspension or adherent platforms with capacities up to 2,000L, with integrated downstream purification; targeted at gene therapy developers.
• Analytical Development Assay design, optimization and validation services for biologics including potency, identity, purity, and stability assays aligned with ICH and global regulatory guidelines; targeted at biopharma manufacturers and advanced therapy developers.
• Assay Transfer

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Cell and Gene Therapy CatapultcoreStrategic or Co-development PartnerCollaboration with the Cell and Gene Therapy Catapult to develop delivery technologies for cell and gene therapies. The partnership focuses on advancing manufacturing and delivery platforms for advanced therapy medicinal products, leveraging Catapult's expertise in translation and industrialization of cell and gene therapies.
• AldevroncoreTechnology or IntegrationRenewal and expansion of lentiviral plasmid licensing agreement. The partnership provides Minaris access to Aldevron's proprietary plasmid technology for use in lentiviral vector manufacturing for cell therapy programs.
• Genetix BiotherapeuticscoreStrategic or Co-development PartnerExpanded manufacturing partnership for LYFGENIA, a gene therapy product. Minaris provides expanded GMP manufacturing capacity and capabilities for the commercial production of LYFGENIA, representing a significant expansion of the existing partnership.
• Chimeric TherapeuticscoreStrategic or Co-development PartnerStrategic collaboration on CDH17 autologous CAR-T program for solid tumor indication. Minaris provides GMP manufacturing and development services for Chimeric's novel CAR-T therapy targeting CDH17, a promising target for solid tumor cancers.
• Janssen (Johnson & Johnson)coreOEM/ Whitelabel/ Licensing PartnerJanssen has licensed Minaris's TESSA® AAV production technology for use in their advanced therapy programs. This licensing arrangement represents commercial validation of Minaris's proprietary AAV manufacturing platform and generates royalty revenue.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Lonza Cell & Gene Technologies: Lonza is the largest dedicated cell and gene therapy CDMO, offering viral vector and cell therapy manufacturing services globally. Directly competes with Minaris in AAV, lentiviral, and cell therapy manufacturing for biotech and pharma clients.
• Catalent (Novo Holdings): Catalent provides cell and gene therapy CDMO services including viral vector and cell therapy manufacturing following its acquisition by Novo Holdings. Overlaps with Minaris across AAV, lentiviral vector, and cell therapy GMP manufacturing for clinical and commercial supply.
• WuXi Advanced Therapies (WuXi AppTec): WuXi AppTec operates a global cell and gene therapy CDMO with viral vector and cell therapy manufacturing capabilities. Directly comparable to Minaris in scale, services, and global footprint, serving biotech clients developing ATMPs.
• Resilience: Resilience is a US-based cell and gene therapy CDMO offering viral vector, cell therapy, and biologics manufacturing. Direct competitor in clinical and commercial CGT manufacturing, with overlapping customers and technology platforms.
• AGC Biologics: AGC Biologics provides cell and gene therapy CDMO services including viral vector and cell therapy manufacturing across facilities in the US, Europe, and Asia. Directly competes with Minaris in GMP viral vector and cell therapy production for global biotech clients.
• Scorpius BioManufacturing: Scorpius BioManufacturing is a US-based biologics and cell/gene therapy CDMO offering mammalian and microbial manufacturing services. Directly comparable to Minaris in serving CGT developers, though with a smaller commercial footprint.

Broad incumbents

• Thermo Fisher Scientific (Brammer Bio / Patheon Viral Vector Services): Thermo Fisher operates a large viral vector and cell therapy CDMO business built on the Brammer Bio acquisition, alongside broader pharma services. Directly competes with Minaris in viral vector manufacturing but offers a much wider portfolio including drug product, clinical trials, and analytical services.
• Samsung Biologics: Samsung Biologics is expanding from large-scale biologics manufacturing into cell and gene therapy services. Comparable to Minaris in GMP manufacturing capabilities but operates at significantly larger scale and broader service scope.

Emerging players

• Cellares: Cellares is an emerging cell therapy manufacturing technology company developing automated, closed-system cell therapy manufacturing platforms (Cell Shuttle). Targets the same autologous and allogeneic cell therapy CDMO market as Minaris with a differentiated automation approach.

Others

• Aldevron: Aldevron is a leading plasmid DNA and viral vector manufacturer serving gene therapy and cell therapy developers. Functions as both a supplier and partner to Minaris (lentiviral plasmid licensing agreement) and an adjacent CDMO competing for upstream plasmid work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/minaris

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minaris Advanced Therapies